BUSINESSQUARTZ
AbbVie is buying an eczema and asthma drug developer for almost $11 billion
AbbVie is acquiring a drug developer for nearly $11 billion in cash to gain access to zumilokibart, an experimental drug that could rival Dupixent in treating atopic dermatitis.
Related Signal
Adjacent reporting
- AbbVie would gain an experimental eczema drug by buying biotech: report
- STAT+: AbbVie to buy Apogee Therapeutics in nearly $11B deal
- STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
- Biogen is buying anti-inflammatory drug startup RayThera for up to $1 billion
- AbbVie buys Apogee for $10.9bn to acquire inflammatory disease drug
- STAT+: GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B